New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups .
The PrOSPeCT program will give 23,000 cancer patients free access to genomic profiling and matching to the best advanced precision treatments available locally, including early-stage clinical trials.
AUSTRALIAN cancer patients who have been diagnosed with rare soft tissue sarcomas will now have affordable access to a global therapy shown to improve survival, following its listing on the Pharmaceutical Benefits Scheme (PBS).